[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337627-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337627-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","combining-magnetic-resonance-imaging-with-a-multi-ancestry-polygenic-risk-score-to-improve-identification-of-clinically-significant-prostate-cancer","Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer","","Multi-parametric magnetic resonance imaging (mpMRI) is used to identify clinically significant prostate cancer, defined as grade group 2 or higher. This study assessed whether adding a 400-variant multi-ancestry polygenic risk score (PRS) improves identification. Using Mass General Brigham Biobank data, 1243 men who underwent mpMRI were analyzed. Men in the top PRS quartile showed higher clinically significant cancer frequencies, and PRS use reduced missed clinically significant cancers in a biopsy-selection scenario from 9.1% to 5.9%, supporting PRS-assisted identification of potentially lethal disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/combining-magnetic-resonance-imaging-with-a-multi-ancestry-polygenic-risk-score-to-improve-identification-of-clinically-significant-prostate-cancer/337627/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/combining-magnetic-resonance-imaging-with-a-multi-ancestry-polygenic-risk-score-to-improve-identification-of-clinically-significant-prostate-cancer/337627.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of adding a PRS to mpMRI in this study?","Question",{"text":63,"@type":64},"To determine whether a 400-variant multi-ancestry PRS, when added to mpMRI, could improve identification of clinically significant prostate cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did PRS level relate to clinically significant prostate cancer frequency?",{"text":68,"@type":64},"Men in the top PRS quartile had higher clinically significant cancer frequency than those in the bottom quartile, and this was true among both mpMRI-positive and mpMRI-negative men.",{"name":70,"@type":61,"acceptedAnswer":71},"What impact did PRS have in a biopsy-selection scenario?",{"text":72,"@type":64},"Using the PRS lowered the frequency of missed clinically significant cancers from 9.1% to 5.9%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337627,1790156030,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":124,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","JNCI Cancer Spectrum, 2024, 8(2), pkae014  \n[https://doi.org/10.1093/jncics/pkae014](https://doi.org/10.1093/jncics/pkae014)  \nAdvance Access Publication Date: March 1, 2024  \nBrief Communications  \nCombining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer  \nAnna Plym , PhD,1,2,3,􀀃 Ikenna Madueke, MD/PhD,1 Sachin Naik, BComm,4 Mark Isabelle, BA,4 David V. Conti, PhD,5 Christopher A. Haiman , ScD,5 Kathryn L. Penney , ScD,2,6 Lorelei A. Mucci , ScD,2 Rhamin Khorasani, MD,4 Adam S. Kibel, MD1  \n1Department of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden  \n4Center for Evidence-Based Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA  \n5Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA  \n6Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA  \n􀀃 Correspondence to: Anna Plym, PhD, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden (e-mail: [anna.plym@ki.se](anna.plym@ki.se)) .  \nAbstract  \nMulti-parametric magnetic resonance imaging (mpMRI) has emerged as an important tool for identifying clinically significant prostate cancer. We examined if the addition of a 400-variant multi-ancestry polygenic risk score (PRS) to mpMRI has the potential to improve identification. Based on data from 24 617 men from the Mass General Brigham Biobank, we identified 1243 men who underwent mpMRI. Men in the top PRS quartile were more likely to have clinically significant prostate cancer (47.1% vs 28.6% in the bottom PRS quartile, adjusted relative proportion 1.72 [95% CI ¼ 1.35 to 2.19]) . Both among men with a positive and a negative mpMRI, men in the top PRS quartile had the highest frequency of clinically significant cancer. In a constructed scenario for selecting men to undergo biopsy, use of the PRS lowered the frequency of missed clinically significant cancers from 9.1% to 5.9% . Our study provides initial support for using the PRS to improve identification of potentially lethal prostate cancer.  \nMulti-parametric magnetic resonance imaging (mpMRI) aids in targeting prostate lesions for biopsy and has emerged as an important tool for identifying clinically significant prostate cancer, defined as grade group 2 or higher (Gleason score 7 or higher) cancer (1-3) . Based on the Prostate Imaging–Reporting and Data System (PI-RADS) v. 2. 1, mpMRI has a sensitivity of 87% and a specificity of 74% to detect clinically significant cancer (4), and the proportion of clinically significant cancer increases from 0% for PI-RADS score 1 to 80% for PI-RADS score 5 (5) .  \nWhile mpMRI is predominantly used in men with elevated prostate-specific antigen, men with a high genetic predisposition may be another target population. Prostate cancer is the most heritable cancer, and 451 germline risk variants for prostate cancer have been identified to date (6) . Combined into a polygenic risk score (PRS), these variants have been shown to robustly stratify men according to prostate cancer risk. A criticism of the PRS has been that it cannot distinguish between prostate cancers of low and high risk of metastatic progression, ie, the PRS has, at least historically, been equally strongly associated with nonaggressive and aggressive disease (7) . For a new 400-variant multiancestry PRS that excludes 51 variants linked to prostate-specific antigen levels (potentially influencing the ability to detect disease), a consistently stronger association with aggressive","cbCaifQi0IqdH3jY","https://ap.wps.com/l/cbCaifQi0IqdH3jY","pdf",414884,"English","# Abstract\n## Study objective and approach\n## Key findings\n## Clinical implications","[{\"question\":\"What was the main goal of adding a PRS to mpMRI in this study?\",\"answer\":\"To determine whether a 400-variant multi-ancestry PRS, when added to mpMRI, could improve identification of clinically significant prostate cancer.\"},{\"question\":\"How did PRS level relate to clinically significant prostate cancer frequency?\",\"answer\":\"Men in the top PRS quartile had higher clinically significant cancer frequency than those in the bottom quartile, and this was true among both mpMRI-positive and mpMRI-negative men.\"},{\"question\":\"What impact did PRS have in a biopsy-selection scenario?\",\"answer\":\"Using the PRS lowered the frequency of missed clinically significant cancers from 9.1% to 5.9%.\"}]","Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer | PDF",1790019874,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1ef6a715ed4c8b8c98232440b5c86aa.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6608d44e6ad03c306225d1375811d220.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77508e3b96c3660a19bbb9f89df1100c.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/822b59d44cbf40bb6c9ef749e11ccef1.webp",980,1287]